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Biomarkers encompass a wide range of different measurable indicators, representing a tangible link to physiological changes
occurring within the body. Accessibility, sensitivity, and specificity are significant factors in biomarker suitability. New biomarkers
continue to be discovered, and questions over appropriate selection and assessment of their usefulness remain. If traditionalmarkers
of inflammation are not sufficiently robust in their specificity, then perhaps alternative means of detection may provide more
information. Epigenetic drift (epigenetic modifications as they occur as a direct function with age), and its ancillary elements,
including platelets, secretedmicrovesicles (MVs), andmicroRNA (miRNA), may hold enormous predictive potential.Themajority
of epigenetic drift observed in blood is independent of variations in blood cell composition, addressing concerns affecting
traditional blood-based biomarker efficacy. MVs are found in plasma and other biological fluids in healthy individuals. Altered
MV/miRNA profiles may also be found in individuals with various diseases. Platelets are also highly reflective of physiological
and lifestyle changes, making them extremely sensitive biomarkers of human health. Platelets release increased levels of MVs in
response to various stimuli and under a plethora of disease states, which demonstrate a functional effect on other cell types.
1. Introduction
Biomarkers encompass a wide range of different measurable
indicators, including protein, polysaccharides, and nucleic
acids, and are distinct, both quantitatively and qualitatively,
from common circulating biomolecules, such as albumin.
They represent a tangible link to physiological changes occur-
ring within the body and ideally enable diagnostic and/or
prognostic evaluations to be determined with respect to dis-
ease. Accessibility, sensitivity, and specificity are significant
factors in biomarker suitability. The initiation and progres-
sion of atherosclerosis are traditionally measured by internal
intima-medial thickness (IMT) [1]. However, detection of
inflammatory processes through use of biomarkers may
facilitate earlier diagnosis well before the clinical threshold
and enable preventive remedial action to be taken. A number
of commonly used indicators exist, and their wide use in
the clinical setting reported in literature indicates large
consensus of their efficacy. Nevertheless, new biomarkers
continue to be discovered, and questions over appropriate
biomarker selection and assessment of their usefulness as
reliable indicators of disease remain. In this context, the
emerging field of epigenetics has enormous potential as
biomarkers of cardiovascular risk. By analysing environmen-
tally induced changes in chromosomes and monitoring these
alterations over time, determination of the epigenetic “drift”
is possible. Such data have the potential to provide novel
therapeutic targets for vascular-associated chronic illnesses
and initiate novel drug-development pipelines.
2. CVD and Problems Posed
Cardiovascular disease (CVD) is an umbrella term for a
class of diseases involving the cardiovascular system and
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consequently includes heart failure, arrhythmia, angina,
hypertension, high cholesterol, and stroke amongst oth-
ers. Vascular inflammation is a key contributor to CVD
etiology, with inflammation and CVD risk factors closely
interrelated. CVD risk factors, such as hypertension, and
hypercholesterolemia are associated with higher circulating
concentrations of inflammatory biomarkers [2]. Types of
CVD are varied and complex; hence there are multiple
pathological mechanisms through which disease may arise.
Atherosclerosis is the most common of the vascular inflam-
matory diseases. It is defined as chronic, specifically affecting
arterial blood vessels, and caused by dynamic dysfunction
of the endothelium. Endothelial dysfunction is regarded as
the earliest detectable indicator of CVD and is used as an
independent predictor of future disease occurrence [3].
Dysregulation of endothelial homeostasis is characterised
by reduced availability of nitric oxide and is an acknowledged
marker of early atherogenesis [4] and a multistage process.
Following injury, the resulting immune response leads to
inflammation at the site. Macrophage cells are typically the
first type to respond.They act by secreting proteins (cytokines
and chemokines) in order to recruit additional immune
cells to the site of injury [5]. Vascular Cellular Adhesion
Molecule 1 (VCAM1) and Intracellular Adhesion Molecule 1
(ICAM1) are other important mediators in cell-cell and cell-
matrix interactions during inflammation and resultant aber-
rant immune response. As such, theymay all act as “biomark-
ers” of inflammation. However, their use is relatively broad.
Biomarkers of associated inflammatory responses yield
an alternative/indirect means of detection. Oxidative stress,
for example, is widely associated with atherosclerosis,
myocardial infarction, and so forth and is known to play a
critical role in the genesis and continuance of inflammation
through interruption of normal cell signaling mechanisms
[6]. As such, a host of related biomarkers have been employed,
including high-sensitivity C-reactive protein (C-RP) and
interleukin-1, interleukin-6, and interleukin-10 [7, 8].
A recently published longitudinal study conducted over
a twenty-year period investigated the relationship between
subclinical atherosclerosis and a host of biomarkers including
cytokines/adipokines, thrombosis, and adhesion molecules.
IMT measurement was used as control and conducted over
four time-points during the investigative period. The test
group consisted of 886 individuals with type 1 diabetes.
Logistic regression models carried out by the team suggest
that individual biomarkers were not predictive of/associated
with subclinical atherosclerosis. However, composite scores
of acute-phase reactants, cytokines/adipokines, and throm-
bolytic factors were nevertheless associated with higher levels
of atherosclerosis at Epidemiology of Diabetes Interventions
and Complications (EDIC) year 12 [1].
3. Predictor Potential versus Risk
Assessment and Robustness
While biomarkers of other diseases may be derived from
surgical biopsy, in terms of detecting vasculature-derived
disease, blood represents perhaps the simplest and most
logical of sources from which to obtain biological markers.
Analysis of blood and bodily fluids in general has emerged
as a form of “liquid biopsy.” This has primarily been used
in the field of cancer diagnosis but equally holds promise for
diagnosis of other conditions.
One of the major difficulties in identifying suitable
biomarkers is determining those which independently signal
a change within the system, without becoming overwhelmed
by the myriad of processes surrounding them. Sensitivity
and specificity are paramount [9]. Numerous signalling
molecules, such as inflammatory cytokines, are proposed
as important factors related to atherosclerotic pathogenesis.
Tumor necrosis factor alpha (TNF𝛼), for example, is widely
used as amarker of vascular inflammation [10, 11]. Cung et al.
[12] acknowledge that it is readily capable of activating
endothelial cells (ECs). However, they state that, due to
the presence of thousands of other factors, the discrete
assessment of individual cytokines, such as TNF𝛼 or CD40,
may fail to capture the global inflammatory stimulus that the
blood conveys to the endothelium. As such, they believe that
the complex composition of blood results in a tangible gap
between biomarker and clinical outcome.A similar sentiment
is shared in another recent publication, where the presence of
interferons due to the presence of disease inhibited biomarker
interpretation [13]. This conflicts with the use of nuclear
interferon-inducible-16 (IFI16), which acts as DNA sensor in
inflammasome signalling, andmay also function as a suitable
inflammatory biomarker [14]. It has previously been used
as a biomarker of cognitive dysfunction [15]. Nevertheless,
this is a serious challenge to the usefulness of blood-based
biomarkers [12]. If traditional markers of inflammation are
not sufficiently robust in their specificity, then perhaps alter-
native means of detection may provide more information.
Data from studies carried out by Brindle et al. [16] has
shown that traditional factors, such as smoking and diet, lack
accuracy and may even result in overestimation of disease
risk in low-risk populations and vice versa. Involvement of
hereditary factors may represent a more significant agent in
both vascular remodelling and disease development. Indeed,
with regard to coronary artery disease (CAD), genome-wide
association studies have led to the identification of a large
number of single nucleotide polymorphisms (SNPs) associ-
ated with increased risk of developing the disease [17]. How-
ever, each of these approaches is based on the fundamental
principle that genetic determinants lie within the static DNA
code of individuals; the hypothesis being that a personmay, in
effect, be more susceptible to succumbing to disease based on
their unique genetic profile. Nevertheless, the genetic code of
individuals has long been known to be flexible and adaptable.
Such adaptations may occur in the long term through
evolution or may occur as a more direct reaction to various
external stimuli by means of up/downregulation of genes in
order to best meet the adaptive demands of certain situations.
4. Epigenetics, Aging, and Chronic Disease
Biomarkers discussed thus far are predominantly diagnostic
in nature. However, the emerging field of epigenetics may
hold enormous predictive potential. Owing to the existence
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Figure 1: DNA methylation (writing, reading, and erasing) represents one of a number of means through which epigenetic modification of
DNAmay occur. Methyltransferase enzymes serve to methylate cytosine residues, particularly in CpG islands. Methyl-CpG-binding domain
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of numerous conflicting interpretations of what the term
meant, epigenetics was finally defined in 2008 as “a stably
heritable phenotype resulting from changes in a chromo-
some without alterations in the DNA sequence” [18]. DNA
methylation, the covalent addition/removal ofmethyl groups,
is an example of such independent modification. Histone
protein modification is an area of some debate and had been
considered not to be epigenetically regulated [19], though
current thinking places it firmly within the epigenetic realm
[20]. More recently, noncoding RNA (ncRNA) has also been
included as major players in the epigenetic domain, with
microRNA (miRNA) recognised as having an important
regulatory function. Importantly, epigenetic modifications
persist within the cell [19].
Following methylation and/or histone N-terminal mod-
ification (acetylation, deacetylation, phosphorylation, and
ubiquitylation), the epigenome is altered. Effect on gene
transcription is nuanced andmay vary depending on context.
Regulation of gene expression was originally believed to
occur through alteration of transcriptional start sites (TSSs).
Methylated regions have been linked with particular chro-
matin features associated with transcriptional repression,
especially H3K9me3 and methyl-CpG-binding protein 2
(MECP2). Methylation in other regions of the genome is
increasingly accepted as having functional relevance and
presents fundamentally more dynamic patterns of methyla-
tion than those discovered in TSSs [21]. There, for exam-
ple, methyl-binding domain (MBD) proteins may serve to
coalesce DNA, which, as with TSSs, then recruit histone
deacetylases and effectively silence that sequence. Current
research indicates that CpG methylation is notably avoided
at sites close to TSSs. It has been proposed that those TSSs
that are methylated exhibit long-term silencing [21].
In contrast to silencing, transcriptional stimulation may
instead occur as a result of methylation. This has been
observed largely in regions located away from TSSs, a phe-
nomenon termed the “DNAmethylation paradox” [22]. Fur-
thermore, over 50% of vertebrate genes contain short (∼1 kb)
CpG-rich sequences, with the remaining genome deplete
of such regions. In mammalian cells, methylation gener-
ally occurs within CpG dinucleotides, typically in cytosine
residues that are followed by guanine. Hence, development
of detailed epigenome maps in normal and disease states
(and thus understanding the distribution of methylation
across the genome) is requisite to understanding the function
of DNA methylation [21]. The methylation mechanism is
highly regulated and, importantly, is a fluid, dynamic, and
reversible process, orchestrated through a complex network
of epigenetic writer, reader, and erasers (see Figure 1).
Epigenetic drift is the term given to epigenetic modifica-
tions as they occur as a direct functionwith age.While age is a
known risk factor for many diseases, age-related methylation
has been found to occur differentially at specific sites along
the genome. Hence, investigation of epigenetic drift may
result in the discovery of key underlying biomarkers of
numerous age-related pathologies [23]. Research has shown
that tissue-specific age-associated CGs are commonly found
outside CpG islands with decreased methylation. Such sites
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Figure 2: Epigenetic drift over time can result in measurable differences between biological and chronological age. Epigenetic changes have
been found to be reflective of lifestyle and may act as functional biomarkers of disease before clinical threshold is reached.
have been linked with higher tissue-specific expression levels
compared to those with increasedmethylation [24, 25]. Some
debate has arisen as to the complexity of the methylation
mechanism. Recent studies by Valencia-Morales Mdel et al.
[25] favour a common instructive mechanism. However, Day
et al. [24] believe a much more complex mechanism than a
simple epigenetic driftmodel is at play.The later theorywould
suggest that epigenetic methylation could potentially repre-
sent a viable type of biomarker. Indeed, DNA methylation-
derived measures of aging have been found to predict
mortality independently of health status and other known
genetic factors [26]. The aging effects of epigenetic drift over
time are highlighted in Figure 2.
Physical activity (PA) is a modifiable lifestyle choice, with
enormous health and fitness benefits. Regular PA is a known
requirement tomaintain a healthy cardiovascular system [27]
and has been shown to produce a long-term anti-inflamma-
tory effect in vasculature [28]. Recent efforts have been made
to assess the effects of exercise as an epigenator in DNA from
a variety of tissues. Human skeletal muscle has been found to
be influenced by exercise applied as a physiological stressor.
Genes previously found to be differentially methylated in
type 2 diabetes (PGC-1𝛼, PPAR-𝛿, TFAM, citrate synthase,
and PDK4) were evaluated, and methylation was found to be
lower following acute exercise. Muscle-specific transcription
factors remained unchanged [29].
Rather than taking baseline single point blood sample
measurements, stressing the cardiovascular system (in vivo
instead of in vitro stress models) by prescribed exhaustive
exercise or by the use of acute models of physical inactivity
may provide much more valuable and conclusive evidence in
relation to the body’s response to stress. Among the first to
employ global DNAmethylation pattern analysis was a study
investigating the effects of a six-month exercise intervention
onDNAmethylation in adipose tissue of healthymen. Results
demonstrated genome-wide DNA methylation changes, and
17,975 individual CpG sites exhibited altered levels of DNA
methylation in response to exercise [30]. Conversely, a
separate study by Horvath et al. [31] in adipose tissue using
the same methylation change data as a comparator found
that such short-term weight loss did not impact the DNA
methylation age of the tissue.
Obesity, often associated with sedentary lifestyle, has
been demonstrated in another study as an accelerant of epige-
netic change. Methylation was found to occur in DNA from
liver tissue in direct correlation with body mass index (BMI)
[32]. This corresponds with evidence uncovered by Horvath
et al. [31], in a comparable study where the relationship
betweenDNAmethylation andBMI in a variety of tissueswas
examined, including liver. The authors were able to discern
and validate age acceleration in this tissue. Importantly,
results highlighted tissue-specific changes, indicating that
individual CpG sites may be unsuitable for global compar-
isons between differing tissue types. Instead, an aggregate
approach, validated across cells, complex tissues, and organs,
was proposed and used in the analysis. Furthermore, the
authors call for caution in the use of BMI as a measure of
adiposity, instead, citing muscle mass in association with
methylation as a more suitable measure of epigenetic aging
for this type of research.
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5. Arterial Remodelling and Blood
Blood vessels are readily capable of remodelling/altering
themselves in response to hemodynamic prompts associated
with variations in blood flow. Significant variations of flow
pattern occur, such as that produced in response to exer-
cise or sedentary behaviour. In some cases, these may be
pathological flow types that lead to aberrant remodelling
and development of disease status. Calls were recently made
for deeper investigation into possible correlation between
sedentary behaviour and vascular function, particularly in
children [3]. A number of studies used the example of
the relationship between sedentary television viewing time
and cardiovascular risk. Gabel et al. [33] investigated the
relationship between sedentary television viewing time in
children (aged 7–10 years) and inflammatory and endothelial
function biomarker levels. Here, the team found that fol-
lowing adjustment for age, weight, sex, and so forth, each
additional hour per week of television viewing was associated
with 4.4% (95% CI: 2.1, 6.7) greater C-RP and 0.6% (0.2,
1.0) greater VCAM-1. The authors advocate a more rigid and
longer study to fully assess this association. Nevertheless, the
relationship between sedentary lifestyle and inflammation
was clearly drawn. As such, any further investigation could
potentially involve epigenetic markers.
The complex composition of blood as a challenge to
biomarker efficacy, discussed previously, was examined in a
recent publication by Yuan et al. [23], where whole blood
tissue was analysed for epigenetic drift. Key amongst the find-
ings was the fact that the majority (80%) of epigenetic drift
observed in blood was independent of variations in blood
cell composition. When adjusted for composition, results
demonstrated a reduction in epigenetic drift attributable to
the increase in the granulocyte : lymphocyte ratio, with a con-
comitant enrichment of age-hypermethylated CpG islands.
This is a significant boost for the use of epigenetic biomarkers,
where traditional types have been found to succumb to
sensitivity and specificity issues.
6. Circulating Biomarkers: Microvesicles,
miRNA, and Platelets
There can be no doubt that markers of endothelial dysfunc-
tion and epigenetic screening may be of prognostic value
in detection of disease. In the immediate future, however,
microvesicles (MVs) may represent a more feasible opportu-
nity to translate potential prognostic biomarkers to clinical
practice. These secreted vesicles permit reprogramming of
recipient cells and are easily obtained in bodily fluids [34].
Different types of MVs are released by mammalian cells
into the extracellular space, including blood. Critically, they
carry membrane and cytosolic components [35] and main-
tain both a similar topology and antigenic signature to the
parent/donor cell and yet may be extracted from sites distal
to the parent cell within the body via blood. MVs are found
in plasma and other biological fluids in healthy individuals.
Altered MV profiles may also be found in individuals with
various diseases [36].Theymay be released under a variety of
different circumstances, for example, when cells undergo the
natural processes of apoptosis or necrosis or when injured.
MVsmay be divided into one of the three categories, outlined
in Table 1.
Due to their origin from different cell types, their dif-
ferential mechanism of biogenesis, and resultant variable
composition, MV effector function is believed to be similarly
varied. As such, it is believed that microvesicles represent
detectable units involved in intercellular exchange. Indeed,
particular biomarkers have been associated with particular
types of vesicles; for example, the presence of CD80 and
CD86 is indicative that exosomes found in plasma may be
of antigen presenting cell (APC) origin [37]. In terms of the
vasculature, endothelial cell-derived microparticles (MPs),
therefore, display characteristic antigen markers that allow
for their identification and detection. An interesting aspect
of MP surface marker research is the requirement of specific
techniques to generate MPs that carry specific markers. For
example, work carried out by Takahashi et al. [38] included
generation of aortic EC-derived MPs bearing VE-cadherin
in response to TNF𝛼 stimulation. Neither hydrogen peroxide
(H
2
O
2
) nor cigarette smoke extract (as the study also looked
at pulmonary vascular ECs) treatment of the same cell
type yielded a similar result. Furthermore, the relationship
between expression levels of particular antigens and levels
detectable on MPs did not appear to directly correlate.
Examinations on circulating endothelial- and platelet-
derived MPs have been conducted. Findings suggest that
levels of circulating endothelial and platelet MPs correlate to
the size of myocardium at risk in patients with ST-elevation
myocardial infarction. This is indicative of the fact that they
reflect the severity of endothelial injury andplatelet activation
during myocardial ischemia [39].
Aswith cytokines, discussed previously, the sheer number
of MVs present in vasculature from all cell types may
present an overarchingmasking effect that renders individual
effects difficult to perceive. Of interest is research carried out
by Garnacho-Montero [40] on the reliability of circulating
cell-free DNA (cf-DNA) concentrations, compared to C-
RP, procalcitonin (PCT), and eosinophil count, in infection
diagnosis in patients with systemic inflammatory response
syndrome. Results showed that cf-DNA levels did not corre-
late with C-RP or PCT in septic patients. Those with acute
myocardial infarction (known to increase cf-DNA levels)
were excluded from the study. No research has so far been
conducted with regard to the reliability of cf-DNA as an
indicator of vascular inflammation.
7. MicroRNA
Perhaps one of the most important components of MPs is
miRNA.These are short noncoding RNAmolecules, approx-
imately 22–25 nucleotides in length [41], the actual length
of which is defined by the specific argonaute involved in its
genesis [42]. Since their discovery in 1993, during experimen-
tation on the nematode, Caenorhabditis elegans [43], the field
of research has expanded to encompass genome-wide studies.
Current opinion hails miRNA asmolecules of vast regulatory
potential [44]. Target identification/characterisation remains
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Table 1: Microvesicle class based on size, origin, and composition.
Microvesicle type Size (𝜇m) Formation Internal composition External composition
Exosome <0.1 Exocytosis Cytoplasm, protein,miRNA, mRNA
Plasma membrane and
surface proteins of parent
cell
Microparticle 0.1–1.0
Cell stress/stimuli
Cell membrane asymmetry
and cytoskeletal
deregulation
Cytoplasm, protein,
miRNA, mRNA
Apoptotic body >1.0 Apoptosis
Cytoplasm, protein,
miRNA, mRNA,
nuclear fragments
a significant challenge, given the vast numbers of miRNAs so
far discovered.
Nevertheless, a number of potential circulatory miRNA
markers have been determined. Of those investigated thus
far, mir-155 has been revealed as an important herald of
inflammatory response. Analysis of both in vitro and in vivo
models has revealed mir-155 to be involved in a negative
feedback loop. Impeding mir-155 resulted in downregulation
of inflammatory cytokines, IL-6 and TNF𝛼. Absence of these
cytokines served to impede atherosclerotic development.
Significantly, mir-155 is postulated to be responsible for post-
translational regulation of the MAPK pathway by targeting
MAP3K 10 [45].
8. Platelets Act as Biomarkers
Circulating blood platelets are 2–4 𝜇m sized anucleate frag-
ments of precursor cells called megakaryocytes. Their pro-
duction is arguably the most elegant and distinct develop-
mental process in eukaryotes [46]. An obvious advantage of
using platelets as biomarkers of human health and disease
is their fast, simple, and minimally invasive accessibility
from whole blood in large numbers, representing the second
most abundant cell type in blood. Platelets are also highly
reflective of physiological and lifestyle changes, making them
extremely sensitive biomarkers of human health. Although
anucleate, platelets retain a sophisticated repertoire of mes-
senger RNA, miRNA, and protein which contribute to pri-
mary (adhesion, activation, secretion, and aggregation) and
alternative (immune regulation, inflammation, RNA transfer,
and tumour metastasis) functions [47].
Typical biomarkers of platelet health include identifi-
cation of primary platelet function changes in activation,
aggregation, and secretion. A multitude of techniques, most
notably flow cytometry (to measure glycoprotein activation-
dependent changes, exposure of granule membrane pro-
teins, platelet-leukocyte aggregate, etc.), aggregometry, and
Enzyme-Linked Immunosorbent Assay (ELISA) have pre-
viously been used to identify these changes. Lack of stan-
dardisation between labs and preactivation of platelets due to
methodological pitfalls are major problems when analysing
platelet-derived biomarkers, warranting a pressing require-
ment for reliable platelet biomarkers [48].
9. Platelet miRNA as Epigenetic Biomarkers
It has been well documented that activated platelets also
release the most abundant cell-derived MVs, accounting for
70–90% of circulating peripheral MVs. These MVs harbour
an array of cell components including protein, DNA, and
RNA and can act as a network of communication by selec-
tively interacting with target cells. Platelets release increased
levels of MVs in response to various stimuli and under
a plethora of disease states including CVD, cancer, and
neurodegenerative diseases.
10. Platelet miRNA Has a Functional
Effect on Other Cells
The modern “omics” revolution enables simultaneous quan-
tification of hundreds of molecules from a single sample and
may bemore reflective of platelet function changes, providing
novel biomarkers for a range of diseases [47]. Platelets
provide considerable contribution to the circulating miRNA
pool and their harboured miRNAs have been labelled as
markers of mature megakaryocyte miRNA [49]. As platelets
are anucleate and have a limited lifespan, platelet-derived
miRNA could represent an ideal marker of temporal and
modifiable epigenetic drift [48].
Furthermore, studies by Laffont et al. [50] and Gidlo¨f
et al. [51] demonstrate the functionality of platelet miRNA,
whereby functional complexes of miR-223 and Argonaute
2 protein (Ago2) packaged in MVs from activated platelets
couldmodulate expression of targeted endothelial cellmRNA
transcripts FBXW7 and EFNA1. This same complex has also
been shown to reduce expression levels of another tran-
script, the insulin-like growth factor 1 receptor in endothelial
cells, and promote human umbilical vein endothelial cell
(HUVEC) apoptosis [52]. This type of platelet MV-cell
interaction is illustrated in Figure 3.
11. Platelet miRNA as a Biomarker of CVD
Platelets play a key role in CVD progression where the
normal platelet response is modified by enhanced proaggre-
gatory processes and decreased antiaggregatory mechanisms
thereby generating a condition of platelet hyperaggregability
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on an acute and chronic level. Following atherosclerotic
plaque rupture in severe CVD states, platelets adhere to the
disrupted plaque and aggregate to form a prothrombotic
surface, subsequently encouraging thrombosis and vascular
occlusion. Platelet miRNAs have been differentially impli-
cated in the presence and progression of a range of diseases,
including but not limited to various CVDs such as Acute
Coronary Syndrome (ACS), Atrial Fibrillation (AF), and
coronary artery disease (CAD) [53].
Platelet miRNA profiles are differentially expressed in
ACS. In a study by Ward et al. [54], blood was obtained
from 13 patients with ACS presenting with either ST Segment
Elevation Myocardial Infarction (STEMI) or Non-ST Seg-
ment ElevationMyocardial Infarction (NSTEMI). In STEMI,
the artery is usually completely occluded as compared to
NSTEMI, which displays partial occlusion [55]. Four platelet
enriched miRNAs were differentially expressed between
groups. Platelet enriched miR-186-5p and miR-342-3p were
significantly lower in patients with STEMI as compared with
NSTEMI. In contrast, platelet enriched miR-25-3p and miR-
221-3p were significantly higher in patients with STEMI as
compared with NSTEMI.
Circulating levels of the platelet enriched miR-328 have
also been linked to AF in 2445 offspring in the Framingham
Heart Study [53].This miR controls particular genes involved
in inflammation, vascular function (ABCG2), cell signalling,
and cellular aging (H2AFX), which constitute some of the
mechanisms in the development of AF. miR-328 expression
was decreased in subjects with AF in comparison to sub-
jects without AF. Furthermore, in a separate investigation,
Sondermeijer et al. [56] demonstrated bymicroarray analysis
that platelet-derived miRNAs (miR-624 and miR-340) were
significantly elevated in CAD patients compared to healthy
individuals.
12. Platelet Mitochondria as a Biomarker
Investigation of metabolic function in platelets for disease
diagnosis and prognosis is a new area of translational research
[57]. Platelets contain functional mitochondria whose activ-
ity is modulated in different pathological states such as CVD
[58]. This suggests that platelets can sense metabolic stress
and act as surrogate markers of mitochondrial dysfunction
in remote inaccessible tissue types [59].
The traditional role of mitochondria in the platelet was
considered to supply energy in the form of ATP for pri-
mary platelet functions: adhesion, activation, and aggrega-
tion. However, novel functions for mitochondria continue
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to emerge. Mitochondrial membrane potential (ΔΨm) is
reduced in a subtype of platelets known as Collagen and
Thrombin Activated (COAT) platelets. Dual activation of
platelets with collagen and thrombin results in striking alter-
ations in function and structure. COAT platelets differ from
typical “activated platelets” by exhibiting a myriad of features
such as phosphatidylserine exposure due to cytoskeletal reor-
ganisation, high microparticle release, and increased levels of
fibrinogen on the platelet surface. In addition, mitochondria
have been noted to be involved inATP-controlled thrombotic
signalling and platelet apoptosis [60].
13. Platelet mtDNA Methylation
Platelets have a higher degree of ATP turnover than resting
mammalianmuscle which holds high levels of mitochondria,
suggesting a critical role formitochondria in platelet function
and huge requirement for energy during platelet activation.
As with nuclear DNA, mitochondrial DNA (mtDNA) has
the potential to be methylated by factors such as disease,
ageing, and environmental exposure, moderating control
of mitochondrial gene expression. In tandem with platelet
miRNA biomarkers, simultaneous understanding of epige-
netic regulation of mitochondrial genes in platelets is proving
crucial to understanding their implication in CVD develop-
ment. Recently, Baccarelli and Byun [61] investigated platelet
mtDNA methylation in a selection of mitochondrial genes
including NADH dehydrogenase (MT-MD5), cytochrome c
oxidase (MT-CO1, MT-C02, and MT-C03), tRNA leucine
1 (MT-TL1), and ATP synthase (MT-ATP6 and MT-ATP8)
amongst CVD patients and healthy individuals by bisulfite
PCR coupled with pyrosequencing. CVD patients had signif-
icantly higher mtDNA methylation than healthy individuals
inMT-CO1, MT-C02, MT-CO3, andMT-TL1, genes involved
in ATP synthesis.
DNA methylation in platelet mitochondria could be a
potential contributor to CVD development through regula-
tion of platelet function. The role of mtDNA methylation in
platelet function has yet to be fully determined, but this study
is the first to portray platelet mtDNA methylation as being
implicated in, and a possible biomarker of, CVD.
14. Conclusion
Initiation of vascular inflammation is a key event in endothe-
lial dysfunction and CVD as a whole. While a small group
of markers (ICAM, VCAM, IL-6, cytokines, etc.) have been
generally accepted by the scientific community, questions
remain regarding the overall biological relevance, as both
reporters and effectors of pathophysiological processes.
Epigenetic biomarkers may yield far-reaching prognostic
results but, as a technique, is in its infancy. Nevertheless,
epigenetic alterations in vasculature have potential to provide
novel therapeutic targets for vascular-associated chronic
illnesses and initiate novel drug-development pipelines.
Yet, significant challenges remain. Deeper investigation
into the physiological roles ofMVs in vivo is required. A great
deal about MVs remains unknown; even their biogenesis is
yet to be completely understood. A concerted effort must
be made in the direction of MV profiling. Knowledge of
miRNA and their associated pathways will prove necessary in
order to understand effects on cells and, importantly, unlock
their diagnostic and predictive potential. The observation
of proinflammatory miRNA upregulation in stimulated MPs
suggests that MV miRNA currently presents perhaps the
most compelling opportunity for significant progress in the
field of vascular research. Platelet miRNA signature may well
quantitatively reflect platelet activation in vivo and therefore
could have huge potential as biomarkers of cardiovascular
risk. In addition, correlating platelet physiology and function
with its miRNA content may provide new insights into the
changes in age and lifestyle-associated epigenetic drift. To
this end, it is essential to identify and subsequently interpret
miRNA functionality and hence distinguish which of these
are most relevant in a clinical setting.
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